EPREX-10000 IU

7,300.00৳ 

  •  Size Guide

    Size Guide

  •  Delivery & Return

    Delivery

    Store delivery FREE

    1-3 working days

    Home or collection point from £35.00 FREE

    On all your orders for home or collection point delivery

    Returns

    Return

    We will accept exchanges and returns of unworn and unwashed garments within 30 days of the date of purchase (14 days during the sales period).

    Returns in store FREE

    Your return will usually be processed within a week to a week and a half. We’ll send you a Return Notification email to notify you once the return has been completed. Please allow 1-3 business days for refunds to be received to the original form of payment once the return has been processed.

  •  Ask a Question
  ... people are viewing this right now

  Share
Guaranteed Safe CheckoutTrust

 

Medicine Overview of Eprex 4000IU Injection

Introduction

Eprex is a medicine that helps your bone marrow to produce more red blood cells. It is used to treat a type of anemia caused by kidney disease. It is also used to treat anemia caused by cancer chemotherapy and by taking medicines to treat HIV.

Eprex is given by injection either under the skin or into a vein which will be decided by your doctor. Usually the injections are given by a nurse or doctor. The dose depends on your body weight and the cause of your anemia. Iron supplements both before and during treatment may make this treatment more effective. Eprex needs to be stored in a fridge but used at room temperature.

The most common side effects of taking this medicine include nausea, vomiting and increased blood pressure. It may also cause flu-like symptoms such as headache, tiredness, dizziness and aches and pains. These side effects are most common at the start of treatment but if they persist your doctor may be able to suggest ways of preventing or reducing them. Tell your doctor straight away if you get any serious side effects, including seizures (fits). Sometimes this medicine can cause serious blood clots which need urgent medical attention.

Before using Eprex you should tell your doctor if you have uncontrolled high blood pressure, heart disease or gout (disease of joint pain). You should also tell him/her what other medicines you are taking in case they affect this treatment. Your blood pressure should be checked often during this treatment by you or your doctor. You may also need other regular medical tests to be sure this medicine is not causing harmful effects. It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant, plan to become pregnant or are breastfeeding.

 

Uses of Eprex
  • Anemia due to chronic kidney disease
  • Anemia due to cancer chemotherapy
Side effects of Eprex
Common
  • High blood pressure
  • Nausea
  • Fever
  • Vomiting
How to use Eprex
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Eprex works
Eprex is an erythropoiesis-stimulating agent (ESA). It works by stimulating the bone marrow (soft tissue inside the bones which produces red blood cells) to produce more red blood cells.
What if you forget to take Eprex?
If you miss a dose of Eprex, please consult your doctor.
Quick Tips
  • Eprex helps in the treatment of anemia that may have occurred due to chronic kidney disease or cancer chemotherapy.
  • It is given as a single injection under your skin.
  • Your doctor may get your blood tests done regularly to monitor the levels of hemoglobin, blood cells and electrolytes such as potassium in your blood.

     

  • Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, problems with your eyesight, nausea, vomiting or fits (seizures).

     

  • Stop taking Eprex and inform your doctor if you develop shortness of breath or skin rash.
Brief Description
Indication
Anaemia of chronic renal failure, Anaemia in zidovudine-treated HIV-infected patients, Anemia related to non-myeloid malignant disease chemotherapy, To reduce the need for allogenic blood tranfusion, Anaemia of prematurity.

 

Adult Dose
Chronic Kidney Disease-Associated Anemia
Reduction of need for red blood cell (RBC) transfusion in patients with chronic kidney disease (CKD)
Patient not on dialysis: 50-100 units/kg IV/SC 3 times weekly initiallyInitiate only when (1) hemoglobin level <10 g/dL, (2) rate of hemoglobin decline indicates likely necessity of RBC transfusion, and (3) reducing risk of alloimmunization or other risks related to RBC transfusion is goal; if hemoglobin level >10 g/dL, reduce or interrupt dose and use lowest dose sufficient to reduce need for RBC transfusion

Patient on dialysis: 50-100 units/kg IV 3 times weekly initially

Initiate when hemoglobin level <10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose

Zidovudine-Related Anemia
Treatment of anemia due to zidovudine administered at <4200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of <500 milliunits/mL
100 units/kg IV/SC 3 times weekly initially

Chemotherapy-Related Anemia
Treatment of anemia in patients with nonmyeloid malignancies where anemia is due to effect of concomitant myelosuppressive chemotherapy for >2 months
150 units/kg IV/SC 3 times weekly initially; alternatively, 40,000 units SC once weekly until completion of chemotherapy course

Preparation for Surgery With High Risk of Blood Loss
Reduction of need for allogeneic RBC transfusions in patients with perioperative hemoglobin >10 g/dL but ?13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery
300 units/kg SC once daily for 15 consecutive days (10 days preceding surgery, day of surgery, 4 days following surgery); alternatively, 600 units/kg SC in 4 doses administered 21, 14, and 7 days before surgery and on day of surgery

 

Child Dose
Chronic Kidney Disease-Associated Anemia
<1 month: Safety and efficacy not established
>1 month: 50 units/kg IV/SC 3 times weekly initially; if patient on dialysis, IV route recommendedInitiate when hemoglobin level <10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose

Prematurity-Related Anemia
25-100 units/kg SC 3 times weekly or 200-400 units/kg SC/IV q24-48hr for 2-6 weeks

Zidovudine-Related Anemia
<8 months: Safety and efficacy not established
8 months-17 years: 50-400 units/kg SC/IV 2-3 times weekly

Chemotherapy-Related Anemia
<5 years: Safety and efficacy not established
5-18 years: 600 units/kg IV once weekly; not to exceed 40,000 units

 

Contraindication
Hypersensitivity to albumin (human) or mammalian cell-derived products; uncontrolled hypertension.
Mode of Action
Epoetin alfa stimulates the differentiation and proliferation of erythroid precursors, release of reticulocytes into the circulation and synthesis of cellular Hb thus regulating erythropoiesis.

 

Precaution

Hypertension; history of seizures; thrombocytosis; chronic liver failure; poor renal function; ischaemic vascular disease; malignant tumours. Increased risk of thrombotic events. Monitor BP during treatment. Regularly monitor platelet counts and serum-potassium concentration. Iron deficiency, infection or inflammatory disorders, haemolysis, or aluminium intoxication will reduce efficacy. Proper dosage control is required to prevent to rapid increase in the haematocrit and haemoglobin levels. Pregnancy; lactation.

Lactation: Unknown whether drug is excreted in breast milk; use with caution; avoid administering multidose vials

 

Side Effect
>10%
Pyrexia (10-42%),Nausea (11-35%),Hypertension (14-27%),Cough (4-26%),Vomiting (12-28%),Pruritus (12-21%),Rash (2-19%),Headache (5-18%),Arthralgias (10-16%)1-10%
Arthralgia (10%),Myalgia (10%),Stomatitis (10%),Diarrhea (9%),Dizziness (9%),Edema (9%),Fatigue (9%),Weight decrease (9%),Medical device malfunction (artificial kidney clotting during dialysis) (8%),Vascular occlusion (vascular access thrombosis) (8%),Vomiting (8%),Asthenia (7%),Chest pain (7%),Injection-site irritation (7%),Muscle spasm (7%),Upper respiratory tract infection (URTI) (7%),Urticaria (3%),Seizures (2.5%),Pulmonary embolism (1%),Respiratory tract congestion (1%)

 

Pregnancy Category Note
Pregnancy
Limited data available on epoetin alfa use in pregnant women are insufficient to determine a drug-associated risk of adverse developmental outcomesAnimal data
In animal reproductive and developmental toxicity studies, adverse fetal effects including embryo-fetal death, skeletal anomalies, and growth defects occurred when pregnant rats received epoetin alfa at doses approximating the clinical recommended starting doses
Consider the benefits and risks of epoetin alfa for the mother and possible risks to the fetus when prescribing epoetin alfa to a pregnant woman

Lactation
There is no information regarding the presence of epoetin alfa products in human milk, the effects on the breastfed infant, or the effects on milk production

However, endogenous erythropoietin is present in human milk

Because many drugs are present in human milk, exercise caution when epoetin alfa is administered to a lactating woman

 

Interaction

Cyclosporine, hematinic agents, drugs that decrease erythropoiesis. Potentiated by hematinic agents.

0.00
0 reviews
5
0
4
0
3
0
2
0
1
0
Be the first to review “EPREX-10000 IU”

Your email address will not be published. Required fields are marked *

This field is required.

This field is required.

This field is required.

Reviews

There are no reviews yet.

Categories
Tags
My Cart
Wishlist
Recently Viewed
Compare Products (0 Products)
Compare Product
Compare Product
Compare Product
Compare Product
Categories

EPREX-10000 IU

7,300.00৳ 

Request a Call Back

    EPREX-10000 IU

    7,300.00৳ 

    Ask a Question